Sartorius Stedim Biotech stock
Price history
+19.02% over the period1 year: from €190.05 (November 17, 2025) to €226.20 (November 16, 2026), +19.02%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €226.20 |
| October 30, 2026 | €223.40 |
| September 30, 2026 | €212.80 |
| August 31, 2026 | €196.00 |
| July 31, 2026 | €166.70 |
| June 30, 2026 | €181.60 |
| May 29, 2026 | €178.10 |
| April 30, 2026 | €156.70 |
| March 31, 2026 | €166.20 |
| February 27, 2026 | €183.10 |
| January 30, 2026 | €188.30 |
| December 31, 2025 | €210.00 |
| November 28, 2025 | €207.30 |
| November 17, 2025 | €190.05 |
At a glance
The company
Produce instruments and consumables for biopharmaceutical manufacturing, including bioreactors, cell culture media, purification systems, and lab analytics software
Latest results
Quarter to September 30, 2026 · EPS €1.18 (estimate €1.21)
TickerLandia's take on Sartorius Stedim Biotech
- Pricier than usual relative to earnings: P/E on the latest fiscal year 83 vs a median of 65 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 67 vs 42 (+60%) in a group of 10.
- Strong point: Market momentum (85/100 in its group). Weak point: Financial strength (28/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.00% from the 52-week high
Analysts · 13 analysts
Average target€250.00+11.01% vs. price
Buy 12 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: Sartorius Stedim Biotech
Compared with similar companies: very strong momentum.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh76
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 28.6 78 P/E (trailing 12 months) 66.9 82 Price/book 4.96 63 Price/sales 7.08 72 Forward P/E 36.8 84 Profitabilityaverage49
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 19.2% 66 Gross margin 44.6% 34 Net margin 10.6% 60 ROE 7.7% 40 ROA 4.6% 43 Earnings stabilitylow40
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 8.1% 16 Growthaverage43
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +48.50% 59 Average revenue growth (3 years) −5.29% 7 Revenue growth (year over year) +8.00% 63 Financial strengthlow28
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 3.90 25 Debt/equitycounts in reverse: lower means more financial strength 0.53 41 Current ratio 1.22 25 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.79 20 Dividendlow34
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 27 years 71 Dividend yield 0.3% 11 Payout ratio 20.7% 19 Market momentumvery strong85
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +27.32% 97 Relative strength (6 months) +32.82% 94 1-year return +15.38% 57 Distance from 200-day average +21.45% 91 Riskhigh69
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.2% 62 Maximum drawdown (12 months) 32.1% 74 Beta (1 year) 1.03 73
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sartorius Stedim Biotech is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Sartorius Stedim Biotech's P/E today is 82.9, above the median of its last 10 fiscal years (64.6; between 31.8 and 107.3 from 2016 to 2025). Sartorius Stedim Biotech's P/E (trailing 12 months): 67.0, +60% against the median of a group of 10 similar companies (41.9).
Compared with 10 similar companies
| Metric | Sartorius Stedim Biotech | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 67.0 | High | |
| Forward P/E | 36.8 | High | |
| Operating margin | 19.2% | Middle | |
| ROE | 7.7% | Middle | |
| Debt/equity | 0.53 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sartorius Stedim Biotech. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€762.1M
Latest quarter · Q3 2026
Net income
€95.5M
Latest quarter · Q3 2026
Quarterly net margin
12.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €21.72B
- P/E
- 67.0
- EPS
- €3.33
- Volume
- 56.55K
- Daily trading
- €21.17M
- Dividend yield
- 0.31%
- Last ex-dividend on March 31, 2026
How Sartorius Stedim Biotech is changing
All resultsRevenue grew 9.2% a year on average over the last 5 years
Operating margin fell from 30.2% to 18.1%
Profits turn into cash: free cash flow equal to 139% of net income
Returns
Sartorius Stedim Biotech returns with dividends
€1,000 invested in Sartorius Stedim Biotech 5 years ago, on November 16, 2021, would be worth €485 today with dividends reinvested: −51.52% in total, −13.48% per year. On price alone it would be €476 (−52.42%).
| Period | Sartorius Stedim Biotech | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | +5.21% | +5.30% | €1,052 |
| 6 months | +44.45% | +5.35% | €1,445 |
| Year to date | +7.71% | +2.81% | €1,077 |
| 1 year | +19.52% | +3.19% | €1,195 |
| 3 years | +15.14% | +16.88% | €1,151 |
| 5 years | −51.52% | +17.14% | €485 |
| 10 years | +300.60% | +86.14% | €4,006 |
Over the last 6 months it has done better than 77% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment
The chart in detail
Sartorius Stedim Biotech: technical analysis
Sartorius Stedim Biotech is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 58.9% below its all-time closing high (€548.20, September 10, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 58
- Between 30 and 70
- vs 200-session average
- +22.39%
Active signals
The price is moving in an unusually narrow range compared with the last year.
Support and resistance
Price areas where Sartorius Stedim Biotech has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€225.20
- Support€224.50−0.31%2 touches, last on October 6, 2026
- Support€202.70−9.99%3 touches, last on October 2, 2026
- Support€184.10−18.25%3 touches, last on September 14, 2026
Volatility and risk
Over the last year it has moved roughly in line with the CAC 40.
- Beta (1 year) vs CAC 40
- 1.03
- Volatility (60 sessions, annualised)
- 30.1%
- Largest fall in the last year
- −32.06%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Sartorius Stedim Biotech: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Sartorius Stedim Biotech has been January: +4.68% on average, positive in 18 years out of 26. The weakest has been September: −2.07% on average, positive in 10 years out of 27. November, the current month, has been positive in 16 years out of 26 (+0.83% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.68% | +5.31% | 18 of 26 |
| February | +4.67% | +4.93% | 18 of 27 |
| March | +0.34% | +0.89% | 15 of 27 |
| April | +3.21% | +2.37% | 17 of 27 |
| May | +1.93% | +2.62% | 17 of 27 |
| June | +1.70% | +1.38% | 16 of 27 |
| July | +3.48% | +4.17% | 17 of 27 |
| August | +3.12% | +0.58% | 15 of 27 |
| September | −2.07% | −2.38% | 10 of 27 |
| October | +0.07% | −0.15% | 13 of 27 |
| November | +0.83% | +1.49% | 16 of 26 |
| December | +3.22% | +2.93% | 17 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Sartorius Stedim Biotech and its competitors
Based in Aubagne, France, Sartorius Stedim Biotech S.A. has existed since its incorporation in 1978. The company makes instruments and consumables for the biopharmaceutical industry worldwide, among them cell culture media, bioreactors, separation and purification products, storage and transport systems for biological materials, pipettes, sensors, water purification systems and weighing products. Its customers include drug and vaccine manufacturers, food and chemical producers, and research and development laboratories. A collaboration with Bio Usawa Biotechnology, Ltd. covers antibody development in Africa.
- Headquarters
- Aubagne, France
- Employees
- 10,483
- Founded
- 1978
- Chief executive
- Rene Faber
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Sartorius Stedim BiotechDIM | $24B | 19.2% | 67.0 | +44.45% |
| Straumann HoldingSTMN | $20.69B | 24.7% | 47.1 | +30.05% |
| SartoriusSRT | $19.89B | 17.8% | 79.3 | +37.44% |
| ColoplastCOLO.B | $16.93B | 25.7% | 37.2 | +27.77% |
| AlconALC | $35.8B | 12.9% | 57.3 | +23.24% |
| Ypsomed HoldingYPSN | $6.77B | 36.2% | 34.3 | +44.57% |
Same industry or related industries, similar size. Compare Sartorius Stedim Biotech with its competitors · Full profile
More on Sartorius Stedim Biotech
- Sartorius Stedim Biotech revenue and financials
- Sartorius Stedim Biotech dividend and valuation
- Sartorius Stedim Biotech stock return
- Sartorius Stedim Biotech employees, headquarters and business
